دورية أكاديمية
Oncological and Functional Outcomes of Whole-Gland HIFU as the Primary Treatment for Localized Prostate Cancer: A Systematic Review.
| العنوان: | Oncological and Functional Outcomes of Whole-Gland HIFU as the Primary Treatment for Localized Prostate Cancer: A Systematic Review. |
|---|---|
| المؤلفون: | Guang ZLP; Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Electronic address: peter_guang@yahoo.dk., Kristensen G; Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Røder A; Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Brasso K; Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. |
| المصدر: | Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Aug; Vol. 22 (4), pp. 102101. Date of Electronic Publication: 2024 Apr 25. |
| نوع المنشور: | Journal Article; Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2009-> : [New York] : Elsevier Original Publication: Dallas, Tex. : Cancer Information Group, c2005- |
| مواضيع طبية MeSH: | Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/therapy, Humans ; Male ; Disease-Free Survival ; High-Intensity Focused Ultrasound Ablation/methods ; High-Intensity Focused Ultrasound Ablation/adverse effects ; Treatment Outcome ; Ultrasound, High-Intensity Focused, Transrectal/adverse effects ; Ultrasound, High-Intensity Focused, Transrectal/methods |
| مستخلص: | Introduction: High-intensity focused ultrasound (HIFU) is regarded as a promising alternative treatment option for localized prostate cancer (PCa) as it has been proposed to offer similar oncologic control to the standard of care, but with significantly reduced treatment-related side effects. This systematic literature review assesses the available evidence of whole-gland HIFU as primary treatment for localized PCa. Methods: MEDLINE (PubMed) was searched for studies investigating oncological and functional outcomes following whole-gland HIFU as primary treatment for localized PCa. Our primary outcomes for the review were biochemical disease-free survival rates (BDFS), overall and PCa-specific survival rates as well as negative biopsy rates. Our secondary outcomes were functional results and complications of the treatment. Results: A total of 375 articles were identified, of which 35 were included in the present review. All 35 articles were prospective or retrospective case series. Mean/median duration of follow-up across studies was 10.9 to 94 months, and 6618 patients were included in the review. The BDFS rate varied greatly across studies from 21.7% to 89.2% during follow-up. The 10-year PCa-specific survival rate following HIFU was 90%, 99%, and 100% in 3 studies. Negative biopsy rates post-HIFU ranged from 20% to 92.7% across studies. Common side effects to HIFU included urinary incontinence (grade 1: 0%-22.7%), erectile dysfunction (11.6%-77.1%), urinary tract infections (1.5%-47.9%), and bladder outlet obstruction mainly as urethral strictures (7%-41.2%). Conclusion: Great variation in oncological and functional outcomes was seen across studies. More prospective trials are needed before whole-gland HIFU can be considered as a treatment option for localized PCa. Competing Interests: Disclosure The authors have stated that they have no conflicts of interest. (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Minimally invasive therapy; Primary intervention; Prostate tumor; Prostatic neoplasm; Transrectal high-intensity focused ultrasound |
| تواريخ الأحداث: | Date Created: 20240529 Date Completed: 20240617 Latest Revision: 20240620 |
| رمز التحديث: | 20240621 |
| DOI: | 10.1016/j.clgc.2024.102101 |
| PMID: | 38811288 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1938-0682 |
|---|---|
| DOI: | 10.1016/j.clgc.2024.102101 |